A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.
复制标题
NOS1AP 基因的变异与瑞格列奈对中国 2 型糖尿病患者胰岛素抵抗的疗效相关。
DOI：
10.1038/aps.2010.25
复制
发表时间：
2010-04
影响因子：
8.2
通讯作者：
Jia, Wei-ping
中科院分区：
文献类型：
--
作者：
Qin, Wen;Zhang, Rong;Hu, Cheng;Wang, Cong-rong;Lu, Jing-yi;Yu, Wei-hui;Bao, Yu-qian;Xiang, Kun-san;Jia, Wei-ping
关键词：
据报道，口服抗糖尿病药物的个体间变异性较高。参与胰岛素分泌和胰岛素信号通路的神经型一氧化氮合酶衔接蛋白（NOS 1AP）的变异可能解释抗糖尿病药物反应的某些变异性。本研究调查了上海地区新诊断的2型糖尿病患者中NOS 1AP中的SNP rs 10494366与瑞格列奈（一种胰岛素促分泌剂）疗效之间的潜在关联。共招募了104例新诊断的2型糖尿病患者（男性69例，女性35例），并接受瑞格列奈治疗24周。在基线和治疗24周后进行人体测量和临床实验室检查。通过测序进行基因分型。GG、GT和TT基因型之间的BMI、HOMA-IR、HOMA-B和空腹胰岛素水平的基线值存在显著差异（P分别为0.024、0.030、0.005和0.007）。TT基因型携带者基线时存在明显的胰岛素抵抗。瑞格列奈单药治疗24周后，空腹胰岛素（P = 0.019）和HOMA-IR（P = 0.011）的Δ值有显著差异。TT携带者治疗后胰岛素抵抗最轻。混合模型分析显示，该变异仅与瑞格列奈治疗对HOMA-IR有交互作用（P = 0.013）。rs 10494366的一个常见变异与瑞格列奈单药治疗对上海新诊断的2型糖尿病患者胰岛素抵抗的疗效相关
A high degree of inter-individual variability response to oral anti-diabetic drug has been reported. Variations in the neural nitric oxide synthase adaptor protein (NOS1AP) involved in insulin secretion and insulin signal pathway may explain some of the variability in response to anti-diabetic drug. The study investigated a potential association between SNP rs10494366 in NOS1AP and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients. A total of 104 newly diagnosed type 2 diabetes patients (69 men, 35 women) were recruited and treated with repaglinide for 24 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 24-week treatment. Genotyping was performed by sequencing. The baseline value of BMI, HOMA-IR, HOMA-B, and fasting insulin level were significantly different between GG, GT, and TT genotypes (P = 0.024, 0.030, 0.005, and 0.007, respectively). Carriers of TT genotype were in significant insulin resistance at baseline. After 24-week repaglinide monotherapy, the Δ value of fasting insulin (P = 0.019) and HOMA-IR (P = 0.011) were significantly different. TT carriers had the least insulin resistance after treatment. The mixed model analysis showed that the variation had an interaction effect with repaglinide treatment only on HOMA-IR (P = 0.013). A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients.
登录
查看更多内容
影响因子：
37.8
作者：
Duplain, H;Burcelin, R;Scherrer, U
通讯作者：
Scherrer, U
影响因子：
3.3
作者：
Chiang, H. T.;Cheng, W. H.;Tseng, C. J.
通讯作者：
Tseng, C. J.
影响因子：
8.2
作者：
Chu, A. Y.;Coresh, J.;Arking, D. E.;Pankow, J. S.;Tomaselli, G. F.;Chakravarti, A.;Post, W. S.;Spooner, P. H.;Boerwinkle, E.;Kao, W. H. L.
通讯作者：
Kao, W. H. L.
影响因子：
8.2
作者：
He, Ya-yi;Zhang, Rong;Xiang, Kunsan
通讯作者：
Xiang, Kunsan
影响因子：
2.6
作者：
Becker, Matthijs L.;Aarnoudse, Albert-Jan L. H. J.;Stricker, Bruno H. Ch.
通讯作者：
Stricker, Bruno H. Ch.